Dxcover Publishes Research Highlighting Effective Early Detection of Pancreatic Cancer Using Infrared Spectroscopy

Dxcover Publishes Research Highlighting Effective Early Detection of Pancreatic Cancer Using Infrared Spectroscopy




Dxcover Publishes Research Highlighting Effective Early Detection of Pancreatic Cancer Using Infrared Spectroscopy

Study published in Cancers demonstrates how simple, minimally invasive and accurate approaches can represent a powerful aid in earlier detection to improve patients’ prognosis and quality of life

GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover Limited, a clinical stage diagnostics company developing spectroscopic liquid biopsy technology for early detection of multiple cancers, today announced findings from a new study that shows how Dxcover’s infrared platform detects a solid and clear distinction between cancer and control samples when detecting early stage pancreatic cancer, suggesting a great potential for clinical implementation. The data has been published in Cancers. Pancreatic cancer is the seventh leading cause of cancer death and claims more than 460,000 lives per year. It is one of the hardest diseases to detect due to the lack of early symptomatic evidence and fast, simple, and non-invasive diagnostic tests. The carbohydrate antigen (CA) 19-9 test is the blood test used for pancreatic cancer’s detection, but its levels can be raised in symptomatic patients with other non-malignant diseases, or with other tumors in the surrounding area.

Dxcover’s proof-of-concept study, investigating the use of attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy on dried blood serum, focused on the discrimination of both cancer versus asymptomatic (healthy) control samples, and cancer versus symptomatic non-malignant control samples, as a novel liquid biopsy approach for pancreatic cancer diagnosis.

Machine learning algorithms were applied, achieving results of 92% sensitivity and 88% specificity when discriminating between cancers (n = 100) and asymptomatic (healthy) controls (n = 100). An area under the curve (AUC) of 0.95 was obtained through receiver operating characteristic (ROC) analysis. In addition, the test identified cancerous patients among a challenging symptomatic cohort to an AUC of 0.83.

“To our knowledge, this is the largest and most promising proof-of-concept study to date for clinical use of ATR-FTIR spectroscopy in the detection of early and advanced stages of pancreatic cancer. The use of our technology can save over $12 million in health care resources per 5000 cancers detected as well rapidly speed up the process for patients to get the required treatment sooner,” said Dr. Matthew Baker, Chief Technology Officer and co-founder, Dxcover.

About Dxcover Limited

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

For further information go to https://www.dxcover.com/science

Contacts

Media:
Tara Mulloy

tmulloy@macdougall.bio